Paula Guzmán-Sastoque

Ms. Paula Guzmán-Sastoque

orcid
Researcher at Universidad de Los Andes

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in HardwareX
Verified
Journal Article
Open access
CRCristian F. Rodríguez
Cristian F. Rodríguez
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
MGMónica Gantiva-Diaz
Mónica Gantiva-Diaz
SGSaúl C. Gómez
Saúl C. Gómez
VQValentina Quezada
Valentina Quezada
Juan CruzJuan Cruz
Juan Cruz
Although microparticles are frequently used in chemistry and biology, their effectiveness largely depends on the homogeneity of their particle size distribution. Microfluidic devices to separate and purify particles based on their size have been developed, but many require expensive cleanroom manufacturing processes. A cost-effective, passive microfluidic separator is presented, capable of efficiently sorting and purifying particles spanning the size range of 15 µm to 40 µm. Fabricated from Polymethyl Methacrylate (PMMA) substrates using laser ablation, this device circumvents the need for cleanroom facilities. Prior to fabrication, rigorous optimization of the device's design was carried out through computational simulations conducted in COMSOL Multiphysics. To gauge its performance, chitosan microparticles were employed as a test case. The results were notably promising, achieving a precision of 96.14 %. This quantitative metric underscores the device's precision and effectiveness in size-based particle separation.

9 April 2025 in Journal of Nanotheranostics
Verified
Journal Article
Open access
PDF file
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
Cristian F. RodríguezCristian F. Rodríguez
Cristian F. Rodríguez
Maria Camila MonsalveMaria Camila Monsalve
Maria Camila Monsalve
SCStiven Andres Castellanos
Stiven Andres Castellanos
AMAndrés Manrique-Moreno
Andrés Manrique-Moreno
Juan CruzJuan Cruz
Juan Cruz
Nanotheranostics—where nanoscale materials serve both diagnostic and therapeutic functions—are rapidly transforming gene therapy by tackling critical delivery challenges. This review explores the design and engineering of various nanoparticle systems (lipid-based, polymeric, inorganic, and hybrid) to enhance stability, targeting, and endosomal escape of genetic payloads. We discuss how real-time imaging capabilities integrated into these platforms enable precise localization and controlled release of genes, improving treatment efficacy while reducing off-target effects. Key strategies to overcome delivery barriers (such as proton sponge effect and photothermal disruption) and to achieve nuclear localization are highlighted, along with recent advances in stimuli-responsive systems that facilitate spatiotemporal control of gene expression. Clinical trials and preclinical studies demonstrate the expanding role of nanotheranostics in managing cancer, inherited disorders, and cardiovascular and neurological diseases. We further address regulatory and manufacturing hurdles that must be overcome for the widespread clinical adoption of nanoparticle-based gene therapies. By synthesizing recent progress and ongoing challenges, this review underscores the transformative potential of nanotheranostics for effective, targeted, and image-guided gene delivery.

14 November 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
JTJulian Daniel Torres-Vanegas
Julian Daniel Torres-Vanegas
NRNicolas Rincon-Tellez
Nicolas Rincon-Tellez
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
JVJuan D. Valderrama-Rincon
Juan D. Valderrama-Rincon
Juan CruzJuan Cruz
Juan Cruz
Luis H. ReyesLuis H. Reyes
Luis H. Reyes
Outer membrane vesicles (OMVs) are spherical structures that contain a small fraction of the periplasm of Gram-negative bacteria, surrounded by its outer membrane. They are naturally produced and detached from the bacterial surface, participate in diverse biological processes, and their diameter size is in the range of 10–300 nm. OMVs have gained interest in different applications, such as the development of biosensors, vaccines, protein chips, and the encapsulation of heterologous proteins and peptides expressed by these microorganisms. However, the use of OMVs in these applications is limited due to the low yields and high purification costs. In this study, we produced green fluorescent protein (GFP) encapsulated into OMVs using Escherichia coli JC8031 transformed with pTRC99A-ssTorA-GFP to establish the production and purification route. Results showed that the motility of the strain prevents its immobilization in alginate, which hampers the purification of OMVs. To address this issue, a zeolite-based column was used to chromatographically separate the OMVs from smaller particles. Further experiments will be focused on standardizing the production and purification of OMVs at a scalable level.

8 August 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
SSSebastián Sotelo
Sebastián Sotelo
NENatalia P. Esmeral
Natalia P. Esmeral
SASonia Luz Albarracín
Sonia Luz Albarracín
JSJhon-Jairo Sutachan
Jhon-Jairo Sutachan
SESebasti
Sebasti
Introduction: Parkinson’s disease (PD) presents a significant challenge in medical science, as current treatments are limited to symptom management and often carry significant side effects. Our study introduces an innovative approach to evaluate the effects of gdnf overexpression mediated by CRISPRa in an in vitro model of Parkinson’s disease. The expression of gdnf can have neuroprotective effects, being related to the modulation of neuroinflammation and pathways associated with cell survival, differentiation, and growth.Methods: We have developed a targeted delivery system using a magnetite nanostructured vehicle for the efficient transport of genetic material. This system has resulted in a substantial increase, up to 200-fold) in gdnf expression in an In vitro model of Parkinson’s disease using a mixed primary culture of astrocytes, neurons, and microglia.Results and Discussion: The delivery system exhibits significant endosomal escape of more than 56%, crucial for the effective delivery and activation of the genetic material within cells. The increased gdnf expression correlates with a notable reduction in MAO-B complex activity, reaching basal values of 14.8 μU/μg of protein, and a reduction in reactive oxygen species. Additionally, there is up to a 34.6% increase in cell viability in an In vitro Parkinson’s disease model treated with the neurotoxin MPTP. Our study shows that increasing gdnf expression can remediate some of the cellular symptoms associated with Parkinson’s disease in an in vitro model of the disease using a novel nanostructured delivery system.

28 May 2025 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Cristian F. RodríguezCristian F. Rodríguez
Cristian F. Rodríguez
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
ASAlan Santacruz-Belalcazar
Alan Santacruz-Belalcazar
CRCoryna Rodriguez
Coryna Rodriguez
PVPaula Villamarin
Paula Villamarin
JCJuan C. Cruz
Juan C. Cruz
Magnetoliposomes represent a transformative advancement in nanomedicine by integrating magnetic nanoparticles with liposomal structures, creating multifunctional delivery platforms that overcome key limitations of conventional drug carriers. These hybrid systems enable precision targeting through external magnetic fields, controlled release via magnetic hyperthermia, and real-time theranostic capabilities, offering unprecedented spatiotemporal control over therapeutic administration. This manuscript focused primarily on studies from 2023-2025 however, a few select older references were included to provide background and context.This review examines the fundamental design principles of Magnetoliposomes, including bilayer composition, nanoparticle integration strategies, and physicochemical properties governing their biological performance. We comprehensively assess synthesis methodologies - from traditional thin-film hydration to advanced microfluidic approaches - highlighting their impact on colloidal stability, drug encapsulation, and scaling potential. Characterization techniques essential for quality control and regulatory approval are systematically reviewed, followed by applications across oncology, gene delivery, neurology, and infectious disease treatment, supported by recent experimental evidence. While magnetoliposomes show remarkable therapeutic versatility, their clinical translation requires addressing biocompatibility concerns, manufacturing scalability, and regulatory hurdles. Integration with artificial intelligence, organ-on-chip technologies, and personalized medicine approaches will likely accelerate their development toward clinical reality, potentially revolutionizing treatment paradigms for complex diseases through tailored therapeutic interventions.

22 August 2024 in Micromachines
Verified
Journal Article
Open access
PDF file
Cristian F. RodríguezCristian F. Rodríguez
Cristian F. Rodríguez
Paula Guzmán-SastoquePaula Guzmán-Sastoque
Paula Guzmán-Sastoque
CMCarolina Munoz
Carolina Munoz
Luis H. ReyesLuis H. Reyes
Luis H. Reyes
Johann F. OsmaJohann F. Osma
Johann F. Osma
Juan CruzJuan Cruz
Juan Cruz
Superparamagnetic iron oxide micro- and nanoparticles have significant applications in biomedical and chemical engineering. This study presents the development and evaluation of a novel low-cost microfluidic device for the purification and hyperconcentration of these magnetic particles. The device, fabricated using laser ablation of polymethyl methacrylate (PMMA), leverages precise control over fluid dynamics to efficiently separate magnetic particles from non-magnetic ones. We assessed the device’s performance through Multiphysics simulations and empirical tests, focusing on the separation of magnetite nanoparticles from blue carbon dots and magnetite microparticles from polystyrene microparticles at various total flow rates (TFRs). For nanoparticle separation, the device achieved a recall of up to 93.3 ± 4% and a precision of 95.9 ± 1.2% at an optimal TFR of 2 mL/h, significantly outperforming previous models, which only achieved a 50% recall. Microparticle separation demonstrated an accuracy of 98.1 ± 1% at a TFR of 2 mL/h in both simulations and experimental conditions. The Lagrangian model effectively captured the dynamics of magnetite microparticle separation from polystyrene microparticles, with close agreement between simulated and experimental results. Our findings underscore the device’s robust capability in distinguishing between magnetic and non-magnetic particles at both micro- and nanoscales. This study highlights the potential of low-cost, non-cleanroom manufacturing techniques to produce high-performance microfluidic devices, thereby expanding their accessibility and applicability in various industrial and research settings. The integration of a continuous magnet, as opposed to segmented magnets in previous designs, was identified as a key factor in enhancing magnetic separation efficiency.